Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small Molecules

Chemistry and Biology

Volumn 13, Issue 7, 2006, Pages 745-751

  Kiessling, Anke ^a   Sperl, Bianca ^a   Hollis, Angela ^a   Eick, Dirk ^b   Berg, Thorsten ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

CELLCYCLE; CHEMBIO; DNA

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; DNA; MYC ASSOCIATED FACTOR X; MYC PROTEIN; PRIMER DNA;

ARTICLE; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; FLUORESCENCE POLARIZATION IMMUNOASSAY; METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN BINDING;

BASE SEQUENCE; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; DIMERIZATION; DNA; DNA PRIMERS; FLUORESCENCE POLARIZATION IMMUNOASSAY; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC;

EUKARYOTA;

EID: 33746239002     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2006.05.011     Document Type: Article

References (34)

1. Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19 (1999) 1-11
2. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6 (2005) 635-645
3. Grandori C., Cowley S.M., James L.P., and Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16 (2000) 653-699
4. Pelengaris S., and Khan M. The many faces of c-MYC. Arch. Biochem. Biophys. 416 (2003) 129-136
5. Pelengaris S., Khan M., and Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2 (2002) 764-776
6. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4 (1999) 199-207
7. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., and Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 (2002) 102-104
8. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004) 1112-1117
9. Pelengaris S., Littlewood T., Khan M., Elia G., and Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3 (1999) 565-577
10. Blackwood E.M., and Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251 (1991) 1211-1217
11. Patel J.H., Loboda A.P., Showe M.K., Showe L.C., and McMahon S.B. Analysis of genomic targets reveals complex functions of MYC. Nat. Rev. Cancer 4 (2004) 562-568
12. Wanzel M., Herold S., and Eilers M. Transcriptional repression by Myc. Trends Cell Biol. 13 (2003) 146-150
13. Adhikary S., Marinoni F., Hock A., Hulleman E., Popov N., Beier R., Bernard S., Quarto M., Capra M., Goettig S., et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123 (2005) 409-421
14. Nair S.K., and Burley S.K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112 (2003) 193-205
15. Fieber W., Schneider M.L., Matt T., Krautler B., Konrat R., and Bister K. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. J. Mol. Biol. 307 (2001) 1395-1410
16. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., and Vogt P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 99 (2002) 3830-3835
17. Xu Y., Shi J., Yamamoto N., Moss J.A., Vogt P.K., and Janda K.D. A credit-card library approach for disrupting protein-protein interactions. Bioorg. Med. Chem. 14 (2006) 2660-2673
18. Chung S., Park S., and Yang C.H. Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation. Cancer Lett. 188 (2002) 153-162
19. Jung K.C., Park C.H., Hwang Y.H., Rhee H.S., Lee J.H., Kim H.K., and Yang C.H. Fatty acids, inhibitors for the DNA binding of c-Myc/Max dimer, suppress proliferation and induce apoptosis of differentiated HL-60 human leukemia cell. Leukemia 20 (2006) 122-127
20. Yin X., Giap C., Lazo J.S., and Prochownik E.V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22 (2003) 6151-6159
21. Mo H., and Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc. Natl. Acad. Sci. USA 103 (2006) 6344-6349
22. Hu J., Banerjee A., and Goss D.J. Assembly of b/HLH/z proteins c-Myc, Max, and Mad1 with cognate DNA: importance of protein-protein and protein-DNA interactions. Biochemistry 44 (2005) 11855-11863
23. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
24. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
25. Amati B., Alevizopoulos K., and Vlach J. Myc and the cell cycle. Front. Biosci. 3 (1998) d250-d268
26. Hopewell R., and Ziff E.B. The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max. Mol. Cell. Biol. 15 (1995) 3470-3478
27. Vogt P.K. Fortuitous convergences: the beginnings of JUN. Nat. Rev. Cancer 2 (2002) 465-469
28. Eferl R., and Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3 (2003) 859-868
29. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., Irby R., Yeatman T., Courtneidge S.A., and Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98 (2001) 7319-7324
30. Sachsenmaier C., Sadowski H.B., and Cooper J.A. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. Oncogene 18 (1999) 3583-3592
31. Wood L.J., Mukherjee M., Dolde C.E., Xu Y., Maher J.F., Bunton T.E., Williams J.B., and Resar L.M. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol. Cell. Biol. 20 (2000) 5490-5502
32. Nilsson J.A., and Cleveland J.L. Myc pathways provoking cell suicide and cancer. Oncogene 22 (2003) 9007-9021
33. Shachaf C.M., and Felsher D.W. Rehabilitation of cancer through oncogene inactivation. Trends Mol. Med. 11 (2005) 316-321
34. Posern G., Sotiropoulos A., and Treisman R. Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. Mol. Biol. Cell 13 (2002) 4167-4178